Sennoside C

Sennoside C is a dianthrone glycoside anthraquinone found in senna (Cassia species) that functions primarily as a stimulant laxative. It is converted by colonic bacteria into rheinanthrone, the active metabolite that stimulates intestinal smooth muscle and alters electrolyte transport to promote bowel movements.

Origin & History

Sennoside C is an anthraquinone glycoside found in the plant Senna alexandrina, also known as Cassia senna. It is typically extracted from the leaves or pods of the plant, resulting in a yellowish powder soluble in water and alcohol.

Historical & Cultural Context

Sennoside C, from Senna alexandrina, has been used in traditional medicine systems like Unani and Ayurveda for over a thousand years. It was commonly included in 19th-century European pharmacopeias as a natural laxative.

Health Benefits

• Increases intestinal motility, aiding in constipation relief (evidence from general senna trials, not specific to Sennoside C).
• Alters colon electrolyte transport, contributing to laxative effects (general evidence for sennosides).
• Inhibits amyloid formation, suggesting potential protein interaction benefits (in-vitro evidence).
• Used traditionally for over a thousand years for bowel regulation (historical use evidence).
• Safe short-term use in adults for improved bowel frequency (general senna studies).

How It Works

Sennoside C is metabolized by colonic microflora into rheinanthrone, which stimulates enteric nerves and smooth muscle via prostaglandin-mediated pathways, increasing peristalsis and intestinal motility. Rheinanthrone also inhibits colonic Na+/K+-ATPase activity, reducing water and electrolyte absorption and increasing luminal fluid content to soften stool. Separately, in vitro research suggests Sennoside C may inhibit beta-amyloid fibril formation, potentially interfering with aggregation pathways relevant to neurodegenerative disease, though this mechanism remains poorly characterized in vivo.

Scientific Research

No key human clinical trials or meta-analyses specifically on Sennoside C were found. Evidence pertains to sennosides broadly, used as a laxative, with general senna trials demonstrating efficacy in constipation relief.

Clinical Summary

Clinical evidence for Sennoside C specifically is sparse; most human trials study mixed sennoside preparations (Sennosides A and B dominant) rather than isolated Sennoside C. Randomized controlled trials of senna-derived sennoside mixtures have demonstrated significant relief of constipation versus placebo in doses of 12–36 mg total sennosides daily, but Sennoside C's individual contribution cannot be quantified from these studies. One in vitro study identified Sennoside C as an amyloid inhibitor, but no human or animal trials have evaluated this effect. Overall, the evidence base for Sennoside C as a distinct compound is preclinical or extrapolated from general senna research, making confident efficacy claims premature.

Nutritional Profile

Sennoside C is a pure isolated anthraquinone glycoside compound (dianthrone glycoside), not a whole food ingredient, and therefore has no conventional macronutrient or micronutrient profile. It is not a source of calories, protein, fat, carbohydrates, vitamins, or dietary minerals in any meaningful nutritional sense. Chemically, it is a heterodianthrone glycoside with molecular formula C₄₂H₃₈O₂₀ and molecular weight of approximately 862.73 g/mol, structurally distinct from Sennosides A and B in that it is a mixed glycoside of rhein and aloe-emodin moieties linked via a C-C bond at the 10,10' position. Bioactive compound concentration: Sennoside C typically constitutes a minor fraction (estimated 1–5%) of the total sennoside content in Senna leaf extracts, compared to the dominant Sennosides A and B which together account for roughly 60–80% of total sennosides. In standardized senna preparations (e.g., 20 mg total sennosides), Sennoside C may be present at approximately 0.5–2 mg. Bioavailability: Sennoside C is poorly absorbed in the small intestine due to its large polar glycoside structure. It is transported largely intact to the colon, where gut microbiota (primarily Bifidobacterium and Eubacterium spp.) hydrolyze the glycosidic bonds and reduce the anthraquinone nucleus to produce active metabolites, principally rhein-anthrone and aloe-emodin-anthrone, which are the pharmacologically active laxative species. Systemic absorption of these metabolites is low (estimated <5% of administered dose reaches systemic circulation). No fiber, protein, lipid, or micronutrient content is attributable to this isolated compound.

Preparation & Dosage

Clinically studied dosages for senna products standardized to total sennosides range from 15-30 mg daily in adults. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Psyllium husk, magnesium citrate, probiotics, ginger, peppermint oil

Safety & Interactions

Sennoside C, like other sennosides, may cause abdominal cramping, diarrhea, and electrolyte imbalances—particularly hypokalemia—with prolonged or high-dose use. Chronic use is associated with melanosis coli, a reversible pigmentation of the colon, and potential dependency if used habitually as a laxative. It may interact with cardiac glycosides (e.g., digoxin) by exacerbating potassium loss, and concurrent use with other laxatives or diuretics increases electrolyte depletion risk. Sennoside-containing products are generally contraindicated in pregnancy beyond occasional short-term use, in intestinal obstruction, and in inflammatory bowel conditions such as Crohn's disease or ulcerative colitis.